— · —
VBIO (VBIO) Stock
$0.28
-2.71%
—: VBIO
—
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Valion Bio's Entolimod Accepted for Regulatory Review in Ukraine
MT Newswires · Jul 22, 2026
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
PR Newswire · Jul 22, 2026
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
PR Newswire · Jul 20, 2026
Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans
MT Newswires · Jul 14, 2026
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
PR Newswire · Jul 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.34%
Institutions Held22.00%
Institutions Float Held22.76%
Peer Comparison
About VBIO
VBIO is led by CEO Michael R. Cavanaugh CPA,, employs 3 people, headquartered in US, publicly traded since 2008.
VBIO stock trades at $0.28 with a market capitalization of $896273. The stock is valued at a price-to-earnings (P/E) ratio of -41.50, price-to-book of 2.59, price-to-sales of 12.11. Over the past 52 weeks the stock has ranged between $0.27 and $5.60, and currently trades 95.0% below its 52-week high.
On profitability, VBIO generates a return on equity (ROE) of -100.00%, return on capital employed of -200.00%, an operating margin of -75.92%, a net profit margin of 3.11%.